This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...